BiotechTube
Home/Gilead Sciences/Linda Grett
LG

Linda Grett

EVP, Pharmaceutical Development & Manufacturing

Gilead Sciences

Therapeutic Areas

VirologyOncologyInflammation

Gilead Sciences Pipeline

DrugIndicationPhase
LenacapavirHIV PrEPPhase 3
Selgantolimod (GS-9688)Chronic Hepatitis BPhase 2
BulevirtideChronic Hepatitis D (U.S.)NDA Submitted
Magrolimab + AzacitidineHigher-Risk MDSPhase 3
TrodelvyHR+/HER2- Metastatic Breast CancerPhase 3 / Approved
YescartaEarlier-line LBCLPhase 3
KITE-363B-cell MalignanciesPhase 1/2
GS-1811Solid TumorsPhase 1

Leadership Team at Gilead Sciences

DO
Daniel O’Day
Chairman & Chief Executive Officer
AD
Andrew Dickinson
Chief Financial Officer
MP
Merdad Parsey
Chief Medical Officer
JM
Johanna Mercier
Chief Commercial Officer
CP
Cindy Perettie
Executive Vice President, Kite Pharma
View full Gilead Sciences profile